Search results
Results from the WOW.Com Content Network
Donepezil, sold under the brand name Aricept among others, is a medication used to treat dementia of the Alzheimer's type. [ 3 ] [ 4 ] [ 8 ] It appears to result in a small benefit in mental function and ability to function. [ 9 ]
The Dementia Training Australia funding an interactive online education package for deprescribing in dementia centered around the MATCH-D. It was a joint collaboration between the University of Western Australia, University of Tasmania, La Trobe University, Monash University, Alfred Health and FireFilms.
Memantine/donepezil, sold under the brand name Namzaric among others, is a fixed dose combination medication used for the treatment of dementia of the Alzheimer's type. [1] It contains memantine, as the hydrochloride, a NMDA receptor antagonist; and donepezil as the hydrochloride, an acetylcholinesterase inhibitor. [1] It is taken by mouth. [1]
The term senile dementia of the Alzheimer type (SDAT) was used for a time to describe the condition in those over 65, with classical Alzheimer's disease being used to describe those who were younger. Eventually, the term Alzheimer's disease was formally adopted in medical nomenclature to describe individuals of all ages with a characteristic ...
Not only that, they had a 52 percent lower risk of vascular dementia, and a 39 percent lower risk of Alzheimer’s dementia. People who took SGLT-2 inhibitors for longer periods of time seemed to ...
Main page; Contents; Current events; Random article; About Wikipedia; Contact us
This isn’t the first time that better sleep has been linked with a lower risk of dementia: A study published in October even found that people with sleep apnea are more likely to develop dementia.
Paraoxon and rivastigmine are both acetylcholinesterase inhibitors and butyrylcholinesterase inhibitors. [14] [11] [7]In 2015, the United States Food and Drug Administration's Adverse Event Reporting System database compared rivastigmine to the other ChEI drugs donepezil and galantamine found that rivastigmine was associated with a higher frequency of reports of death as an adverse event.